Wheless JW, Raskin JS, Fine AL, Knupp KG, Schreiber J, Ostendorf AP, Albert GW, Kossoff EH, Madsen JR, Kotagal P, Numis AL, Gadgil N, Holder DL, Thiele EA, and Ibrahim GM
Purpose: To provide consensus-based recommendations for use of vagus nerve stimulation (VNS) therapy in the management of pediatric epilepsy., Methods: Delphi methodology with two rounds of online survey was used to build consensus. A steering committee developed 43 statements related to pediatric epilepsy and the use of VNS therapy, which were evaluated by a panel of 12 neurologists/neurosurgeons with expertise in pediatric epilepsy, who graded their agreement with each statement on a scale of 1 ("I do not agree at all") to 5 ("I strongly agree"). For each statement, consensus was established if ≥70% of the agreement scores were 4 or 5 and <30% were 1 or 2 in the final survey., Results: Twenty-four statements regarding the need for seizure reduction in pediatric epilepsy, the recommended treatment algorithm, the benefits and safety of VNS therapy, management of side effects of VNS therapy, patient selection for VNS therapy, and the use, dosing, and titration of VNS therapy achieved consensus. VNS and other neuromodulation therapies should be considered for pediatric patients with drug-resistant epilepsy who are not candidates for resective surgery, or who do not remain seizure free after resective surgery. When VNS therapy is initiated, the target dose range should be achieved via the fastest and safest titration schedule for each patient. Scheduled programming can be helpful in dose titration., Conclusion: The expert consensus statements represent the panelists' collective opinion on the best practice use of VNS therapy to optimize outcomes in the management of pediatric epilepsy., Competing Interests: Declaration of competing interest James W. Wheless is a consultant for BioMarin, Epiwatch, Neurelis, Neuro Event Labs, Jazz, and Takeda; has received research funding from LivaNova, Jazz, Neurelis, Neuro Event Labs, Shainberg Foundation, SKLSI, TSC Alliance, and UCB; and serves on the speaker's bureau for BioMarin, Jazz, Neurelis, SKLSI, and UCB. Jeffrey S. Raskin is a clinical advisory board member for Synergia, a consultant for Blackrock Neurotech, Iota, and Brainlab, and President of SMERF, Inc 501(c)(3). Anthony L. Fine has no financial interests to disclose. Kelly Knupp has consulted for UCB, Stoke, Encoded, Epygenix, Longboard and Biocodex; has received research funding from Eisai, Stoke, and UCB; and serves on a Data and Safety Monitoring Board for Jazz and Epygenix. John Schreiber is a clinical advisory board member for Stoke Therapeutics and Longboard Pharmacueticals; a consultant for Denali Therapeutics and Neurocrine; receives research funding to his institution from UCB, Neurocrine, and Stoke Therapeutics; and serves on the speaker bureau for UCB and Marinus. Adam P. Ostendorf receives research funding from NINDS and the Nationwide Children's Hospital Foundation. Gregory W. Albert has no financial interests to disclose. Eric H. Kossoff has received consultant fees from LivaNova (not for this study), Simply Good Foods, Nutricia, Vitaflo, Cerecin, and Bloom Science. He is on the data safety monitoring board for a study from NeuroPace. Joseph R. Madsen is a consultant and scientific advisory board member for BioNaut Laboratories and Anuncia Medical. Prakash Kotagal is a consultant for Biocodex, Inc., LivaNova PLC, SK Life Sciences, and Takeda Pharmaceuticals. Adam L. Numis has no financial interests to disclose. Nisha Gadgil has no financial interests to disclose. Deborah L. Holder is a speaker for LivaNova. Elizabeth A. Thiele is a consultant for Jazz, UCB, Biocodex, LivaNova, Pyros, SKLS, Stoke Therapeutics, Takeda, Marinus, and Nobelpharma. She has received research funding from Jazz, UCB, and Biocodex. George M. Ibrahim has received research funding and consulting fees from LivaNova (not for this study). He also receives consulting and advisory fees from Medtronic Inc and Synergia Inc., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)